Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.69 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447986 | 0.86 | FFAR1 (0.84) | FFAR1RAB9AGFERSMN1; SMN2GAA | |
| SCHEMBL11253749 | 0.85 | GAA (0.57) | FFAR1P4HTMRAB9AGFERSMN1; SMN2 | |
| SCHEMBL5455400 | 0.84 | GAA (0.59) | FFAR1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL11461945 | 0.83 | FFAR1 (0.77) | FFAR1P4HTMFFAR4 | |
| SCHEMBL10055033 | 0.83 | LMNA (0.61) | P4HTMGFERSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL104746 | 0.83 | CA2 (0.62) | FFAR1RAB9AGAAALDH1A1KDM4E | |
| SCHEMBL6419238 | 0.83 | LMNA (0.61) | P4HTMGFERSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL11232512 | 0.83 | FFAR1 (0.71) | FFAR1RAB9AGFERSMN1; SMN2FFAR4 | |
| SCHEMBL20641771 | 0.83 | P4HTM (0.59) | FFAR1P4HTMRAB9AGFERSMN1; SMN2 | |
| SCHEMBL1663181 | 0.83 | PPARA (0.64) | P4HTMGFERSMN1; SMN2GAAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | FFAR1 33/4885P4HTM 1492/4885RAB9A 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.